5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.42▼ | 1.42▼ | 1.42▼ | 1.38▲ | 1.36▲ |
MA10 | 1.42▼ | 1.42▼ | 1.43▼ | 1.30▲ | 1.41▼ |
MA20 | 1.42▼ | 1.44▼ | 1.43▼ | 1.36▲ | 1.24▲ |
MA50 | 1.45▼ | 1.39▲ | 1.34▲ | 1.41▼ | 1.32▲ |
MA100 | 1.42▼ | 1.32▲ | 1.33▲ | 1.22▲ | 1.57▼ |
MA200 | 1.34▲ | 1.35▲ | 1.40▲ | 1.26▲ | 6.37▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | -0.007▼ | -0.009▼ | 0.014▲ | 0.018▲ |
RSI | 42.504▼ | 47.379▼ | 53.185▲ | 52.042▲ | 55.227▲ |
STOCH | 29.167 | 33.889 | 19.266▼ | 54.301 | 47.655 |
WILL %R | -100.000▼ | -83.333▼ | -89.474▼ | -61.222 | -50.240 |
CCI | -146.667▼ | -105.046▼ | -97.124 | 57.712 | 20.473 |
Tuesday, September 16, 2025 08:51 AM
Detailed price information for Pmv Pharmaceuticals Inc (PMVP-Q) from The Globe and Mail including charting and trades.
|
Wednesday, September 10, 2025 12:10 PM
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors ...
|
Wednesday, September 10, 2025 06:31 AM
The NASDAQ 100 Pre-Market Indicator is up 141.13 to 23,980.93. The total Pre-Market volume is currently 120,438,787 shares traded. The following are the most active stocks for the pre-market session: ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/09/25 | 1.44 | 1.47 | 1.37 | 1.40 | 409,827 |
24/09/25 | 1.47 | 1.50 | 1.42 | 1.47 | 1,019,305 |
23/09/25 | 1.35 | 1.4142 | 1.3325 | 1.38 | 1,205,522 |
22/09/25 | 1.30 | 1.35 | 1.285 | 1.34 | 582,106 |
19/09/25 | 1.24 | 1.32 | 1.24 | 1.31 | 811,457 |
18/09/25 | 1.25 | 1.305 | 1.185 | 1.23 | 1,491,726 |
17/09/25 | 1.20 | 1.35 | 1.20 | 1.25 | 1,511,168 |
16/09/25 | 1.13 | 1.25 | 1.1213 | 1.20 | 1,113,629 |
15/09/25 | 1.21 | 1.24 | 1.13 | 1.14 | 961,998 |
12/09/25 | 1.22 | 1.40 | 1.22 | 1.23 | 1,688,930 |
|
|
||||
|
|
||||
|
|